Clinical Trials Browser

Ovarian Neoplasms

NCT05116189 2026-03-09

KEYNOTE-B96

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03740165 2025-10-22

KEYLYNK-001

Phase 3 Active not recruiting

1,367 enrolled 29 charts

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT04201561 2023-06-26

SELENIUM

Phase 3 Unknown

68 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peripheral Nervous System Diseases

NCT05450055 2022-07-13

Intraperitoneal Lidocaine in Ovarian Cancer Surgery

Phase NA Not yet recruiting

60 enrolled

Gynecologic

Ovarian Neoplasms, Pain, Postoperative

NCT00740116 2022-03-15

Tranexamic Acid in Surgery of Advanced Ovarian Cancer

Phase 4 Completed

100 enrolled 11 charts

Gynecologic

Ovarian Neoplasms, Thromboembolism, Blood Loss, Surgical, Postoperative Hemorrhage

NCT00738699 2017-03-30

FAR-122

Phase 2 Terminated

415 enrolled 11 charts

Gynecologic

Ovarian Neoplasms

NCT01432015 2017-03-28

Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting

Phase 4 Completed

20 enrolled 5 charts

Gynecologic

Ovarian Neoplasms, Uterine Neoplasms, Vomiting

NCT02711865 2016-03-17

Predictive Biomarkers for IGF1R Targeted Therapy in Ovarian Cancer

Unknown

20 enrolled

Gynecologic

Ovarian Neoplasms

Clinical Trials

MAIA-ovarian

KEYNOTE-B96

KEYLYNK-001

SELENIUM

Intraperitoneal Lidocaine in Ovarian Cancer Surgery

Tranexamic Acid in Surgery of Advanced Ovarian Cancer

FAR-122

Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting

Predictive Biomarkers for IGF1R Targeted Therapy in Ovarian Cancer